Consent given pursuant to Sections 14 and 14A to the importation and supply of the therapeutic goods specified by Prinz Herget Pty Ltd (T/A Natural Therapy Imports)

Overview

The Therapeutic Goods Act 1989, enacted by the Australian Parliament, serves as the foundational statute for regulating therapeutic goods within Australia. This Act was introduced to ensure that therapeutic goods available in Australia are of acceptable quality, are safe to use when properly administered, and that their benefits outweigh any risks. In particular, the Act aims to safeguard public health by controlling the importation, supply, and registration of therapeutic goods. The Therapeutic Goods Administration (TGA), a branch of the Department of Health, administers the Act and ensures compliance with its provisions. In the case documented in the 2015 Gazette, the TGA addressed a specific issue concerning the labelling of YOMOGI capsules by granting a consent under sections 14 and 14A of the Act, allowing for a temporary deviation from certain labelling requirements for a specified batch until a set date. This consent reflects the TGA's policy objective to balance regulatory compliance with practical considerations, such as the availability of therapeutic products that meet public health needs.

Scope and Application

The Therapeutic Goods Act 1989 applies to a wide range of therapeutic goods within Australia, encompassing medicines, medical devices, and other health-related products. Under this Act, the Therapeutic Goods Administration (TGA) regulates the importation, supply, and advertising of therapeutic goods to ensure they meet safety, quality, and efficacy standards. Section 14 of the Act allows for consent to be granted for goods that do not fully comply with certain regulatory requirements, as demonstrated by the consent given to Prinz Herget Pty Ltd for the importation and supply of YOMOGI capsules. The application of this Act extends to both individuals and entities involved in the importation, supply, or manufacture of therapeutic goods within Australia. The consent granted under Section 14 applies specifically to the entity named, in this case, Prinz Herget Pty Ltd, and to the particular batch of goods specified. The consent provided is geographically limited to the Commonwealth of Australia and is subject to specific conditions and timeframes, as evidenced by the limited consent for batch 530010 until 1 July 2017. Exclusions and exemptions from the requirements of the Act may apply in certain circumstances, but these are determined on a case-by-case basis by the TGA. The Act’s application can be further detailed and specified through subordinate instruments, such as therapeutic goods orders, which outline particular requirements and standards that must be adhered to.

Key Provisions

Sections 14 and 14A of the Therapeutic Goods Act 1989 (the Act) pertain to the consent process for importing and supplying therapeutic goods that do not fully comply with the Therapeutic Goods Regulations. Specifically, section 14 allows the Secretary of the Department of Health to consent to such imports and supplies, while section 14A outlines the conditions under which this consent can be granted. In this case, section 14 was invoked to permit the importation and supply of YOMOGI capsules AUST L 243477 by Prinz Herget Pty Ltd T/A Natural Therapy Imports. These capsules do not conform to the labelling requirements stipulated in Section 3(13), subclauses 3(2)(h) & (i) of the Therapeutic Goods Order No. 69 – General requirements for labels for medicines, particularly regarding the absence of appropriate prefixes for Batch Number and Expiry Date on blister packs. The obligations imposed by the Act on the parties involved include ensuring that any therapeutic goods supplied or imported meet the regulatory standards set forth in the Therapeutic Goods Order. However, under section 14, the Secretary may consent to the supply or importation of goods that do not meet these standards, provided certain conditions are met. In this instance, the consent granted under section 14 is conditional, applying only to batch 530010 and only until 1 July 2017. This consent ensures that the specified therapeutic goods can be supplied or imported within the stipulated conditions, while still maintaining oversight to ensure public safety and regulatory compliance. The Therapeutic Goods Act 1989 also includes provisions for offences, penalties, and consequences for breaches of the Act or its regulations. Breaches of the Act can result in both civil and criminal penalties, depending on the nature and severity of the breach. Civil penalties can include fines up to a significant amount, as determined by the court, for each breach. Criminal penalties can include imprisonment for individuals found guilty of serious offences, with maximum penalties varying according to the specific provision breached. In the case of the consent granted under sections 14 and 14A, failure to adhere to the conditions of the consent could result in enforcement action being taken by the Therapeutic Goods Administration, potentially leading to fines, cancellation of consent, or other regulatory sanctions. Additionally, under section 420 of the Act, any person who contravenes a direction issued by the Secretary under section 14 or 14A is liable to a penalty. The maximum penalty for such an offence can be substantial, reflecting the seriousness of non-compliance with regulatory conditions intended to protect public health. The Therapeutic Goods Administration is empowered to take legal action against entities that fail to comply with the conditions of consent, ensuring that the therapeutic goods supplied or imported remain within the bounds of regulatory approval. This stringent enforcement regime is crucial in maintaining the integrity of the therapeutic goods market in Australia.